Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Biofrontera Inc.

Ticker
BFRI
Sector
Industry
Report date
November 14, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include Biofrontera's Q3 2026 earnings call, FDA approvals and submissions for Ameluz, and reported revenue growth alongside net losses. The company continues to engage in regulatory activities and strategic asset acquisitions.

Recent developments:
  • Biofrontera held its Q3 2026 earnings call providing updates on financial performance and business progress [N1].
  • The company submitted a supplemental new drug application (SNDA) to expand Ameluz's use in actinic keratosis [N3].
  • Biofrontera secured FDA approval for Ameluz SNDA, expanding its approved indications [N4].
  • Q2 2026 results showed a 33% revenue growth, though the company reported a net loss for the period [N6][N7].
  • Biofrontera completed an asset purchase agreement with Pelthos Therapeutics Inc. in November 2025 [S1].
Overview

Biofrontera Inc. is a biotechnology company specializing in dermatological products, including photodynamic therapy treatments such as Ameluz. The company is publicly traded on Nasdaq under the ticker BFRI and is headquartered in Woburn, Massachusetts. Biofrontera engages in clinical development, regulatory submissions, and commercialization of its dermatology-focused therapies. The company has made recent regulatory filings to expand the approved uses of Ameluz and has secured FDA approvals for supplemental indications. Financial disclosures indicate revenue generation alongside net losses, with liquidity ratios reflecting current liabilities exceeding current assets as of Q3 2026. Biofrontera operates as a smaller reporting and emerging growth company, with active investor communications through quarterly earnings calls and public disclosures.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Biofrontera Inc. is a biotechnology company focused on dermatological therapies, notably Ameluz. The company has reported revenue growth and regulatory progress including FDA approvals and submissions for expanded indications. As of Q3 2026, Biofrontera reported a net loss and liquidity ratios below 1, indicating current liabilities exceed current assets. Recent earnings calls and news provide detailed insights into ongoing business developments and financial performance [S1][S2][N1][N3].

Scenarios for BFRI

Bull case model:

Biofrontera has demonstrated regulatory progress with FDA approvals and submissions expanding the indications for its flagship product Ameluz. The company has reported revenue growth, including a 33% increase in Q2 2026, indicating commercial traction. Its focus on dermatological therapies with proprietary photodynamic treatments positions it in a specialized market segment. Ongoing clinical development and regulatory milestones provide potential for further product expansion and market penetration. The company's active investor communications and recent asset acquisitions suggest strategic efforts to strengthen its business.

Bear case model:

Biofrontera continues to report net losses and liquidity ratios below 1, indicating potential financial constraints. The company operates in a competitive biotechnology sector with regulatory risks inherent to drug approvals and market acceptance. Its status as a smaller reporting and emerging growth company may limit access to capital and resources. Delays or failures in regulatory approvals, commercialization challenges, or adverse clinical outcomes could impact business sustainability. The company's reliance on a limited product portfolio increases vulnerability to market and regulatory shifts.

Moat:

Biofrontera's moat is primarily based on its proprietary dermatological therapies, including Ameluz, which has received FDA approval and supplemental approvals for expanded indications. The company's regulatory progress and clinical trial results support its competitive positioning in the niche photodynamic therapy market. However, as a smaller reporting company with ongoing net losses and liquidity constraints, its moat is subject to risks from regulatory, competitive, and financial challenges. The company's ability to maintain and expand its product portfolio through regulatory approvals and commercialization efforts is critical to sustaining its competitive advantage.

Risks overview
Risks summary
Regulatory and financial risks are the most significant, given the company's dependence on FDA approvals and current liquidity constraints.
Risks details:

• Regulatory Risk: Biofrontera's business depends heavily on FDA approvals and regulatory compliance for its products. Delays or denials in regulatory submissions could adversely affect operations.
• Financial Risk: The company reported net losses and liquidity ratios below 1 as of Q3 2026, indicating potential challenges in meeting short-term obligations and funding operations.
• Market Competition: Biofrontera operates in a competitive biotechnology market with risks from competing therapies and changing market dynamics.
• Product Concentration: The company's reliance on Ameluz and related dermatological therapies exposes it to risks if these products face clinical, regulatory, or commercial setbacks.

FINAL FORECAST FOR BFRI

Final take one line
Biofrontera Inc. exhibits very high visibility with detailed regulatory progress, revenue growth, and financial disclosures, balanced by ongoing net losses and liquidity challenges.
Final take 12 to 24 month view

Business trends: Continued regulatory submissions and approvals for Ameluz, revenue growth in dermatological therapies, and strategic asset acquisitions.
Execution milestones: FDA approvals for expanded indications, quarterly earnings reporting, and integration of acquired assets.
Key risks: Regulatory approval delays, financial liquidity constraints, competitive pressures, and product concentration risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Biofrontera Inc. is a publicly traded company on Nasdaq under ticker BFRI [S1].
  • The company is incorporated in Delaware and headquartered in Woburn, Massachusetts [S1].
  • As of March 16, 2026, Biofrontera had 11,648,323 shares outstanding [S1].
  • Biofrontera operates in the biotechnology/medical sector with a focus on dermatological products, including Ameluz, a photodynamic therapy product [N1][N3].
  • The company has submitted supplemental new drug applications (SNDA) to the FDA to expand the use of Ameluz for actinic keratosis and superficial basal cell carcinoma [N3][N1].
  • Biofrontera received FDA approval for Ameluz SNDA, indicating regulatory progress [N4][N1].
  • The company reported revenue of $28.674 million for the fiscal year ended December 31, 2022 [S2].
  • As of September 30, 2026, Biofrontera reported cash and cash equivalents of $3.218 million and current assets of $11.103 million, with current liabilities of $14.237 million, resulting in a current ratio of 0.78 and a cash ratio of 0.23 [S2].
  • The company reported a net loss of $6.423 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.42 [S2].
  • Recent quarterly earnings calls and transcripts provide detailed insights into financial performance and business developments through Q3 2026 [N1][N5].
  • Biofrontera has shown revenue growth, including a 33% increase reported in Q2 2026 [N6].
  • The company completed an asset purchase agreement with Pelthos Therapeutics Inc. in November 2025 [S1].
  • Biofrontera is classified as a smaller reporting company and an emerging growth company [S1].
  • The company has multiple securities registered including common stock and warrants [S1].
  • Biofrontera's business activities include clinical trials, regulatory submissions, and commercialization efforts for dermatological therapies [N1][N3].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
  • N1
  • N5
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-07-22 | 10-K/A
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Biofrontera (BFRI) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/biofrontera-bfri-q3-2026-earnings-call-transcript
  • N2 | 2026-11-05 | www.nasdaq.com | MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/mannkind-mnkd-reports-q3-loss-misses-revenue-estimates
  • N3 | 2026-09-08 | www.nasdaq.com | ISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision | https://www.nasdaq.com/articles/ispecimen-focus-genelux-nears-phase-3-ovarian-cancer-data-biofrontera-awaits-fda-decision
  • N4 | 2026-09-08 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - PDEX +18% On FY'26 Results, ODTX +8%, EOLS, BFRI, DRTS | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-pdex-18-fy26-results-odtx-8-eols-bfri-drts
  • N5 | 2026-08-20 | www.nasdaq.com | Biofrontera (BFRI) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/biofrontera-bfri-q2-2026-earnings-call-transcript
  • N6 | 2026-08-13 | www.nasdaq.com | Biofrontera Posts Strong Q2 2026 Results On 33% Revenue Growth | https://www.nasdaq.com/articles/biofrontera-posts-strong-q2-2026-results-33-revenue-growth
  • N7 | 2026-08-13 | www.nasdaq.com | Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/biofrontera-inc-bfri-reports-q2-loss-beats-revenue-estimates
  • N8 | 2026-08-12 | www.nasdaq.com | BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/biostem-technologies-inc-bsem-reports-q2-loss-beats-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine